<DOC>
	<DOCNO>NCT00530166</DOCNO>
	<brief_summary>The purpose study assess effectiveness JNJ-18054478 measure percent change baseline Forced Expiratory Volume one Second ( FEV1 ) 12 week therapy patient persistent asthma .</brief_summary>
	<brief_title>Effectiveness Safety Study JNJ-18054478 Asthma Patients .</brief_title>
	<detailed_description>Asthma one common chronic disease worldwide . This randomize ( study medication assign chance ) , double-blind study ( neither physician patient know drug receiving , active placebo ) Investigate effectiveness safety 12 week dose JNJ-18054478 ( 300 mg take orally daily ) compare placebo patient persistent asthma . The hypothesis study drug effective treatment asthma placebo measure percent change baseline Forced Expiratory Volume one Second ( FEV1 ) 12 week therapy , without significant adverse event . Safety evaluation include , monitor adverse reaction , clinical laboratory test blood urine , ECGs monitor cardiovascular system , vital sign physical examination . Patients take three capsule ( 100 mg ) JNJ-18054478 orally daily 12 week placebo period .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Medically confirm diagnosis persistent asthma Able demonstrate reversibility least 12 % albuterol inhalation Use shortacting b2 agonist rescue &gt; = 5 time within 2 week prior Able produce FEV1 45 85 % predict Willing perform study procedures 14 week . Use inhale corticosteroid within 4 week Use oral/parenteral corticosteroid within 8 week Use longacting beta2 agonist montelukast within 2 week History lifethreatening asthma attack within 3 month Female child bear potential .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Asthma</keyword>
	<keyword>persistant asthma</keyword>
	<keyword>controller medication</keyword>
	<keyword>FEV1</keyword>
</DOC>